Their goal was to have rotigotine delivered via a patch, since one of the biggest problems plaguing PD patients is keeping the right amount of medication in their systems throughout the day.
But rotigotine has a distinct advantage: It's the first dopamine agonist to be delivered via a patch, thereby allowing patients to have a consistent dose of the drug in their systems at all times.
Schwarz is currently compiling the data from three separate rotigotine trials--two on early stage patients and one on late-stage patients--and the company expects to file for U.S. Food and Drug Administration approval by this fall.